Pipeline

Building superior ADCs

Iksuda ADCs are designed for maximum anti-cancer impact and enhanced therapeutic index, targeting patient sub-groups that are currently poorly-treated.

Our lead programmes target tumours which have limited treatment options and which are associated with high relapse rates.  These include diffuse large B-cell lymphoma, epithelial ovarian cancers, lung adenocarcinomas, triple-negative breast cancers, ductal carcinomas of the pancreas, biliary gastric and colorectal carcinoma.

The first wave of Iksuda ADCs will target antigens that have proven premise in an ADC format with our next-wave focussing on novel antigen targets.

IKS03

CD19
Pre-clinical – 80%
Read more

B-cell cancers

IKS012

FOLR1
Pre-clinical – 60%
Read more

Ovarian, lung, TNBC

IKS02

Undisclosed
Pre-clinical – 0%
Read more

Solid tumours

IKS04

Undisclosed
Research/Discovery – 80%
Read more

Solid tumours